SCHEDULE 13D/A: Talphera Secures Multi-Tranche Financing Up to $7.5 Million Tied to Clinical Milestones

Talphera, Inc. has entered into a Securities Purchase Agreement to raise up to approximately $7.5 million through the issuance of pre-funded warrants and common stock, with subsequent tranches contingent on clinical trial progress and stock price performance.

Summary

• Talphera, Inc. has executed a Securities Purchase Agreement with several purchasers, including Nantahala Capital Partners, NCP RFM LP, Blackwell Partners LLC Series A, and Pinehurst Partners, L.P.
• The agreement facilitates a capital raise structured in three potential closings, with a Per Share Purchase Price of $0.586 and a Price Per Pre-Funded Warrant of $0.585.
• The First Closing involves an aggregate subscription amount of approximately $2.5 million, primarily for Pre-Funded Warrants, which are immediately exercisable.
• The Second Closing, for an additional approximately $2.5 million, is contingent on the public announcement of the enrollment of at least 17 patients in the Company's Niyad NEPHRO CRRT study AND the Common Stock's average VWAP reaching at least $0.7325 (125% of the Per Share Purchase Price) for five subsequent trading days, or a purchaser waiver.
• The Third Closing, for another approximately $2.5 million, is contingent on the public announcement of the enrollment of at least 35 patients in the Niyad NEPHRO CRRT study AND the Common Stock's average VWAP reaching at least $0.7325 for five subsequent trading days, or a purchaser waiver.
• If the Niyad NEPHRO CRRT study is terminated, the right of purchasers to request the Second and Third Closings will terminate.
• Purchasers have the option to receive Pre-Funded Warrants instead of Common Stock to remain below beneficial ownership limitations (4.99% or 9.99%).
• Executive officers and directors of Talphera are subject to Lock-Up Agreements for 90 days following the effective registration of the securities.
• Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, reported a beneficial ownership of 1,992,519 shares, representing 11.7% of the Common Stock, as of April 3, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the financing is dilutive and contingent on future events, securing capital, especially tied to clinical milestones, is a critical positive for a development-stage company like Talphera. It provides necessary funding for operations and R&D, and the milestone-based tranches offer a structured path for future investment, aligning investor interests with company progress.

Positives

• The agreement secures a significant capital infusion for Talphera, with a potential total of approximately $7.5 million, which is crucial for working capital and ongoing operations.
• The multi-tranche structure, tied to specific clinical trial milestones (patient enrollment in the Niyad NEPHRO CRRT study), aligns investor funding with tangible progress in the Company's drug development pipeline.
• The inclusion of a VWAP condition for subsequent closings ($0.7325, 125% of purchase price) provides an incentive for stock price appreciation before additional capital is drawn, potentially benefiting existing shareholders.
• Lock-Up Agreements for executive officers and directors demonstrate management's commitment and alignment with long-term shareholder value.

Negatives

• The issuance of new shares and pre-funded warrants will result in dilution for existing shareholders.
• The Per Share Purchase Price of $0.586 is relatively low, potentially indicating a discount to market or perceived risk.
• The full realization of the capital raise is uncertain, as the Second and Third Closings are contingent on both clinical trial milestones and stock price performance, which may not be met.
• The Company acknowledges that purchasers may engage in hedging activities, including short sales, which could negatively impact the market price of Talphera's publicly-traded securities.

Risks

• **Dilution Risk**: The issuance of new Common Stock and Pre-Funded Warrants will dilute the ownership percentage of existing shareholders.
• **Clinical Trial Contingency Risk**: The Second and Third Closings are dependent on achieving specific patient enrollment milestones (17 and 35 patients, respectively) in the Niyad NEPHRO CRRT study. Failure to meet these milestones or termination of the study would prevent the Company from accessing the full potential capital from this agreement.
• **Market Price Contingency Risk**: The Second and Third Closings also require the Common Stock's average VWAP to be at least $0.7325 for five trading days. If the stock price does not reach this threshold, the Company may not receive the full intended capital, unless purchasers waive this condition.
• **Liquidity and Compliance Risk**: Failure to maintain current public information requirements under Rule 144(c) or other conditions could result in the Company incurring Public Information Failure Payments (liquidated damages) to purchasers.
• **Hedging Activity Risk**: Purchasers may engage in hedging activities, including short sales, which could exert downward pressure on the Company's stock price.
• **Regulatory Compliance Risk**: The Company must comply with SEC filing requirements (e.g., Form 8-K, registration statements) and maintain its listing on the Trading Market; non-compliance could lead to penalties or delisting.

Future Outlook

The agreement outlines a strategic financing path for Talphera, with future capital infusions directly linked to the achievement of key clinical development milestones in the Niyad NEPHRO CRRT study (patient enrollment of 17 and 35) and a specified stock price performance threshold. This structure provides a clear roadmap for potential future funding, contingent on operational and market success.

Management Comments

• Vincent J. Angoth, Chief Executive Officer of Talphera, Inc., signed the Securities Purchase Agreement on behalf of the Company.
• Daniel Mack, Manager of Nantahala Capital Management, LLC, signed the Securities Purchase Agreement on behalf of the Purchasers.
• Taki Vasilakis, Chief Compliance Officer of Nantahala Capital Management, LLC, signed the Schedule 13D/A filing.

Industry Context

This financing structure is common in the biotechnology and pharmaceutical industries, particularly for companies engaged in clinical-stage development. Tying capital tranches to specific clinical milestones, such as patient enrollment, allows companies to secure funding incrementally as they de-risk their pipeline, while also providing investors with clear performance indicators for their investment. This approach helps manage capital burn and aligns investor interests with the company's R&D progress.

Comparison to Industry Standards

• Staged financing tied to clinical milestones is a widely adopted practice in the biotech sector, similar to deals seen with other development-stage biopharmaceutical companies. This approach is often preferred over a single large raise as it provides capital as needed and reduces immediate dilution.
• The beneficial ownership blocker (4.99% or 9.99%) is a standard provision in private placements to prevent triggering certain regulatory reporting requirements or change of control provisions for the purchasers.
• The inclusion of a VWAP condition for subsequent tranches is a protective measure for investors, ensuring that they are investing at a price that reflects some market appreciation, which is a common feature in structured equity financings.

Corporate Governance

Legal Proceedings

• The Company represents that there is no pending or threatened action, suit, inquiry, notice of violation, proceeding or investigation against or affecting the Company that would result in a Material Adverse Effect or challenge the legality, validity or enforceability of the Transaction Documents or Securities.
• Neither the Company nor any current director or officer has been the subject of any action involving a claim of violation of federal or state securities laws or breach of fiduciary duty.
• The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company.

Related Party Transactions

• No officers, directors, or beneficial holders of 5% or more of any class of capital stock, nor employees, are party to any transaction with the Company in excess of $120,000, other than for salary, consulting fees, expense reimbursement, and other employee benefits (including stock options).

Stakeholder Impact

• **Shareholders**: Will experience dilution from the issuance of new shares and warrants. However, the capital infusion provides essential funding for the Company's operations and clinical development, which could lead to long-term value creation if milestones are successfully achieved.
• **Employees**: The financing supports the Company's continued operations and stability, which benefits employees through job security and ongoing project work.
• **Customers/Suppliers**: Indirectly impacted by the Company's improved financial stability, which ensures continuity of business operations and potential for future growth.

Next Steps

• Publicly announce the material terms of the transactions via a press release by the Disclosure Time.
• File a Current Report on Form 8-K with the Commission, including the Transaction Documents as exhibits.
• Apply to list all Shares and Pre-Funded Warrant Shares on The Nasdaq Stock Market LLC and promptly secure their listing.
• Continue to reserve and keep available a sufficient number of Common Stock shares for issuance.
• Timely file a Form D with respect to the Securities as required under Regulation D.
• Take necessary action to obtain exemption for, or qualify the Securities for, sale under applicable state securities or Blue Sky laws.
• Achieve enrollment of at least 17 patients in the Niyad NEPHRO CRRT study to enable the Second Closing.
• Achieve enrollment of at least 35 patients in the Niyad NEPHRO CRRT study to enable the Third Closing.

Key Dates

Recommendation

Keywords

Talphera Inc., Securities Purchase Agreement, Private Placement, Pre-Funded Warrants, Capital Raise, Clinical Trial Milestones, Niyad NEPHRO CRRT study, Dilution, SEC Filing, Schedule 13D/A, Biotechnology, Pharmaceuticals, Financing